Longeveron Inc.
LGVNDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 31, 2026
26dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How LGVN's past catalysts played out
Lomecel-B medicinal signaling cells
Hypoplastic Left Heart Syndrome
Fluzone High Dose Vaccine
Aging Frailty
Allogeneic MSC
Mild Alzheimer's Disease
Longeveron Mesenchymal Stem Cells (LMSCs)
Aging Frailty
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Frailty
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lomecel-B medicinal signaling cells | Phase 2 | Hypoplastic Left Heart Syndrome | - | - |
Fluzone High Dose Vaccine | Phase 2 | Aging Frailty | - | - |
Allogeneic MSC | Phase 2 | Mild Alzheimer's Disease | - | - |
Longeveron Mesenchymal Stem Cells (LMSCs) | Phase 2 | Aging Frailty | - | - |
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Phase 2 | Frailty | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Longeveron Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Longeveron Inc.'s (LGVN) pipeline across Phase 2. Its lead program is Lomecel-B medicinal signaling cells (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Longeveron Inc.'s next FDA catalyst?→
Longeveron Inc.'s (LGVN) next tracked catalyst is a Data Readout expected August 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LGVN biotech catalysts?→
Add LGVN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Longeveron Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.